Neurol. praxi. 2016;17(3):128-132 | DOI: 10.36290/neu.2016.040
Clinical experience with alemtuzumab
- Neurologická klinika 2. LF UK a FN Motol, Praha
Alemtuzumab (Lemtrada) is a humanized monoclonal antibody targeting the surface molecule CD 52 on immune cells. The bond between alemtuzumab and lymphocyte leads to cytolysis resulting to development of new lymphocyte generation potencially without autoaggressive signes of original population. Nowadays, alemtuzumab is in Czech Republic (CR) approved for treatment of highly active relaps–remitting multiple sclerosis (RR MS). In this paper we describe 2 cases of patients on alemtuzumab treatment in our department. We demonstrate both high efficacy confirmed in clinical trials together with potential risk of side effects following from mechanism of action.
Keywords: multiple sclerosis, alemtuzumab, Listeria meningitis, pregnancy
Published: August 1, 2016 Show citation
References
- Brouwer MC, van de Beek D, Heckenberg SG, Spanjaard L, de Gans J. Community-acquired Listeria monocytogenes meningitis in adults. Clin Infect Dis 2006; 43: 1233-1238.
Go to original source... 
Go to PubMed... - De Giglio L, Gasperini C, Tortorella C, Trojano M, Pozzilli C. Natalizumab discontinuation and disease restart in pregnancy: a case series. Acta Neurol Scand 2015; 131: 336-340. Go to original source... Go to PubMed...
- Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler 2015; 21: 22-34. Go to original source... Go to PubMed...
- Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 2015; 8: 31-45. Go to original source... Go to PubMed...
- Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010; 133: 2232-2247. Go to original source... Go to PubMed...
- Meluzínová E. Alemtuzumab v léčbě roztroušené sklerózy. Neurol. praxi 2015; 16(4): 237-240.
- Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, Bayas A. Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis-Report of Two Cases. Int J Mol Sci 2015; 16: 14669-14676. Go to original source... Go to PubMed...
- Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci 2015; 16: 16414-16439. Go to original source... Go to PubMed...